

## HAMDARD INSTITUTE OF MEDICAL SCIENCES AND RESEARCH & ASSOCIATED HAH CENTENARY HOSPITAL JAMIA HAMDARD (Deemed to be University)

GURU RAVIDAS MARG, HAMDARD NAGAR, NEW DELHI -110062

## **Revised: 2022 MBBS Batch 2nd Phase Time Table**

Sr. No.	Day, Date	8 AM to 9 AM	9 AM to 12 Noon	12 Noon to 1 PM	1 PM to 2 PM	2 PM to 3 PM	3 PM to 4 PM
		SU1.1 Describe Basic concepts of homeostasis, enumerate the metabolic changes in injury and their mediators. SU1.2 Describe the factors that affect the metabolic response to injury.		FM 1.1 Basics and definitions, FM 1.2 History, FM1.3 Legal procedures FM1.4 Court procedures	LUNCH BREAK		
1	Saturday, 16 December, 2023		AETCOM			Family Adopt	ion Program
2	Sunday, 17 December, 2023			WEEKLYOFF			
		PA 1.1(L):Describe the role of a pathologist in diagnosis and		MI 1.1 : Introduction and		PA1.3:Practical- Introduction, Histotechnics, Identification of	
3	Monday, 18 December, 2023	management of disease		History (L)		cells:,Microscope	
4	Tuesday, 19 December, 2023	PH 1.1: - (L) principles of pharmacology and Pharmacotherapeutics		PA 1.2 Enumerate common definitions and terms used in Pathology (Lecture)		FM 1.8 Describe the latest decisions related to medico- legal issued by Courts SGD	MI 1.1: Morphology and Physiology of bacteria (SGD)
5	Wednesday, 20 December, 202	PH 1.4: Absorption (L)		PA: 1.3 L: Describe the history and evolution of Pathology	LUNCH BREAK	MI 1.2: Microscopy and I	
6	Thursday, 21 December, 2023	MI 1.4 Sterilization & Disinfection (L)		PA: 2.1 (I)L: Demonstrate knowledge of the causes, mechanisms, types and effects of cell injury and their clinical significance		PH1.6 Describe principles of Pharmacovigilance & ADR reporting systems	
7	Friday, 22 December, 2023	OG 2.1 anatomy of genital tract		PH 1.4-SGD Factors affecting distribution			the principles of ergonomics in (SGD) Describe occupational onals and their prevention &
8	Saturday, 23 December, 2023	od 2.1 anatomy of general tract		4th S A T U R D A Y O F F			
9	Sunday, 24 December, 2023			WEEKLYOFF			
10	Monday, 25 December, 2023			CHRISTMAS			
				PA: 2.1 L(II): Demonstrate knowledge of the causes,		FM2.3 Describe and discuss issues related	MI 8.9: Specimen

	1					concenonana eransport
			mechanisms, types and effect	S	to sudden natural deaths SGD	(SGD)
11	Tuesday, 26 December, 2023	PH 1.4- Distribution ( L)	of cell injury and their clinical		300	
- 11	Tuesday, 20 Becember, 2023	TITT: Fishibution (E)	significance PA:2.2 L: Describe the			
			etiology of cell injury.		DOAP PA.2.3 &	
			Distinguish between		Slide:, Fatty liver ,Hyaline	- Degeneration
			reversible-irreversible		MI 1.5: Sterilisation and	
			injury: mechanisms;		CSSD Visit (P), Grp A/B; N	
		WY 1 4 34 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	morphology of cell injury	LUNCH BREAK	Sterilization & Disinfection	
12	Wednesday, 27 December, 202	PH 1.4-Metabolism (L)	PA: 2.3 SGD: Intracellular	Ecited Break	Sterinzation & Disinfection	iii (30 <i>D)</i>
			accumulation of fats,		PH1.7 Define, identify and d	
		MI: 1.1 Overview of Bacterial infections	proteins, carbohydrates,		management of adverse dru	ıg
13	Thursday, 28 December, 2023	(L)	pigments		reactions (ADR)	
			PH 1.4 –SGD Factors affectin	7		idemiology and describe and
1.4	Edday 20 Day and an 2022	Donation of Madician and Education Madician	metabolism		enumerate the principles, con	ncepts and uses
14	Friday, 29 December, 2023	Practice of Medicine and Ethics in Medicine	FM 1.6 offences, 1.7 dying			
		SU1.3 Describe basic concepts of perioperative	declaration and deposition,			
		care	1.9 Documentation in			
15	Saturday, 30 December, 2023		medical practice		Family Adopti	on Program
16	Sunday, 31 December, 2023		WEEKLYOFF		•	
		PA 2.4 L(I): Describe and discuss Cell death-	MI 1.1 Lab Diagnosis of			: DOAP
		types, mechanisms, necrosis,	Bacterial infections: I,		Slide: Caseous Necros	is, Coagulative Necrosis.
		apoptosis( basic as contrast with	Direct detection, staining			
1.5						
17	Monday, 1 January, 2024	necrosis),autolysis PA:	(L)			
			PA 2.4 L(II): Describe and			
			discuss Cell death- types,		FM1.10 Select appropriate cause of	MI 1.1:
			mechanisms, necrosis, apoptosis( basic as		death in a particular	Conventional methods of bacterial identification
					scenario by referring	(SGD)
10	T1 2 I 2024	PH 1.4 Francisco (I.)	contrast with necrosis),		ICD 10 code	(800)
18	Tuesday, 2 January, 2024	PH 1.4. Excretion (L)	autolysis.		TCD 10 code	
			PA:2.5 SGD: Describe and		10 4 4 6 H	d as allowed a (D)
			discuss pathologic		MI 1.1: Culture media and	a methods (P),
19	Wednesday, 3 January, 2024	PH 1.5 Mechanism Of Action	calcifications, gangrene		(SGD), Grp A/B	
			2.6 SGD: Describe and			
			discuss cellular		PH1.8 Identify and describe	
			adaptations: atrophy,		the management of drug	
			hypertrophy,		interactions	
		MI 1.1 Lab Diagnosis of Bacterial	hyperplasia, metaplasia,			
20	Thursday, 4 January, 2024	infections II	dysplasia	LUNCH BREAK		

		4.1-Describe and discuss the febrile response and the influence of host immune status, risk factors and comorbidities on the febrile response 4.2 Describe and discuss the influence of special populations on the febrile response including: the elderly, immune suppression, malignancy and neutropenia, HIV and travel		PH 1.8: Drug Interactions		CM 7.2 (SDL) Enumerate a transmission and measures f disease. CM 7.3 (SDL) Enu sources of epidemiological of	or prevention and control merate, describe and discuss the
21	Friday, 5 January, 2024	SU2.1 Describe Pathophysiology of shock, types of		(SGD)			
		shock & principles of resuscitation including fluid					
		replacement and monitoring. SU2.2 Describe the					
		clinical features of shock and its appropriate treatment.					
							ature of drugs i.e. generic,
22	Saturday, 6 January, 2024 Sunday, 7 January, 2024		AETCOM	FM 3.1 Identification WEEKLYOFF		branded drugs	
23	Sunday, / January, 2024	PA: 2.7 L: Describe and discuss the mechanisms		WEEKLYUFF		DOA	P PA 2.5
		of cellular aging and		MI 1.1 Bacterial			erg's Calcification,
24	Monday, 8 January, 2024	apoptosis(N)		Genetics- (L)			
	57.			PA:3.1L: Describe the pathogenesis and pathology of amyloidosis		FM1.11 Write a correct cause of death certificate as per ICD 10 document SGD	MI 1.1: Automated and molecular methods of bacterial identification (SGD)
25	Tuesday, 9 January, 2024	PH 1.5 –Receptors (L)		uy.o.u.oo.o			Tuestantual (SGD)
				PA:4.1 L(I): Define and			
				describe the general			
				features of acute and			
				chronic inflammation	LUNCH BREAK		
				including stimuli,	LUNCH BREAK		
				vascular and cellular			
26	Wednesday, 10 January, 2024	PH 1.13: Drug antagonism		events		MI 1.2: Gram staining (P)	, Grp A/B
				PA:4.1 L(II): Define and		PH1.10 Describe parts of a correct, complete and	
				describe the general features of acute and		legible generic prescription	
				chronic inflammation		Identify errors in	
				including stimuli,		prescription and correct	
				vascular and cellular		appropriately	
27	Thursday, 11 January, 2024	MI 1.6 Antimicrobials-1 (L)		events			
	5,	OG 3.1 Physiology of Menstruation,		PH 1.13 (SGD) Bioassay and	i	PH1.12 CM 7.2(Lecture) En	numerate, describe and discuss
		ovulation,fertilization and		biostandardization		the modes of transmission a	nd measures for prevention and
28	Friday, 12 January, 2024					control disease	I
29 30	Saturday, 13 January, 2024 Sunday, 14 January, 2024	Implantation					
30	Sunday, 14 January, 2024	Implantation PA:4.2 L: Enumerate and describe the mediators		NALL C. Antimiorphiala 2 (1)		DA 26 - DO + D CH-J	es - Metaplasia, dysplasia.
31	Monday, 15 January, 2024	of acute inflammation		MI 1.6 Antimicrobials-2 (L)		PA 2.0 ; DUAP Shd	es - Metapiasia, dyspiasia.
				PA:4.3 L: Define and			
				describe chronic			MI 1.6:

	1					IEM 2.10 Investigation of	
				inflammation including causes,		FM 2.19 Investigation of anaesthetic, operative	Antimicrobial
				types enumerate types, non-		deaths SGD	susceptibility testing
				specific and granulomatous;		deaths 3GD	(SGD)
		PH 1.13: (L) Principles of Pharmacovigilance & ADR		and examples of each			
32	Tuesday, 16 January, 2024	reporting systems					
				PA: 5.1 L: Define and			
				describe the process of		MI 1.1: Morphology of co	ommon hacteria
				repair and regeneration		biochemical tests (P), Ba	
		PH 1.14:management of adverse drug reactions		including wound healing		biochemical tests (F), ba	KII A/B
33	Wednesday, 17 January, 2024	(ADR)		and its types			
				PA: 6.1 L: Demonstrate		PH1.12Calculate the	
				knowledge of the causes,		dosage of drugs using	
				pathogenesis, types and	LUNCH BREAK	appropriate formulae	
				effects of edema and their		for an	
				clinical significance		individual patient,	
				cimical significance		including children,	
						elderly and patient	
						with renal	
34	Thursday, 18 January, 2024	MI 1.1: General Virology (L)				dysfunction	
		4.3:Discuss and describe the common causes,					lculate and interpret morbidity
		pathophysiology and manifestations of fever in various		PH 1.13 (SGD) Bioassay and		_	ed on given set of data CM 7.5
		regions in India including bacteria (enteric fever)		biostandardization		(Lecture)Enumerate, define	
		parasitic (Filiariasis, ascariasis)		biostandai dization		epidemiological study desig	ns
35	Friday, 19 January, 2024						
		SU2.3 Communicate and counsel patients and families					
		about the treatment and prognosis of shock					
		demonstrating empathy and care					
36	Saturday, 20 January, 2024		AETCOM	FM 3.2 Identification		Family Adopt	ion Program
37	Sunday, 21 January, 2024			WEEKLYOFF			
		PA: 6.2 SGD: Define & Describe Hyperemia,				PA 2.8Identify and des	scribe various forms of cell
		congestion Hemorrhage				injur	ies, their
						manifestations and c	onsequences in gross and
						mic	roscopic
						spe	cimens
				MI 1.1 Overview of viral			
38	Monday, 22 January, 2024			infections			
						FM2.16 Describe and	
				PA: 6.3 L: Define &	LUNCH BREAK	discuss examination of	
				describe Shock ,its	Lenen bittaik	mutilated bodies or	MI 1.1: Normal microbial
						fragments, charred bones	flora of human body
1				pathogenesis, stages &		and bundle of bones	(SGD)
				clinical correlation		SGD	
39	Tuesday, 23 January, 2024	PH 1.14-(Lecture) Adrenergic agonists					
		PH 1.15: (Lecture) Adrenergic antagonists		PA 6.4.1 SGD : Define and			
				describe normal		MI 1.1: Lab diagnosis of	viral infections (P), Batch A/B
40	Wednesday, 24 January, 2024			haemostasis			
70	" cancoday, 24 January, 2024						

41	Thursday, 25 January, 2024	MI 1.1 General Parasitology (L)	PA: 6.4.2 L: Define and describe the etiopathogenesis and consequences of thrombosis		PH2.1 Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid	
42	Friday, 26 January, 2024	Wil 1.1 General Parasitology (L)	REPUBLICDAY			
43	Saturday, 27 January, 2024		4th S A T U R D A Y O F F			
44	Sunday, 28 January, 2024		WEEKLYOFF			
45	Monday, 29 January, 2024	PA:6.5 L: Demonstrate knowledge of the causes ,types and effects of embolism and the clinical significance.	MI 1.1 Overview of Parastic Infections (L)		PA: 3.2 I Slide: Am	
46	Tuesday, 30 January, 2024	PH 1.16 5-HT (L) Cholinergic agonist	PA;6.6 SGD: Define and describe Ischaemia/infarction its types, etiology, morphologic changes and clinical effects			II 1.1: Microbial athogenesis (SGD)
47	Wednesday, 31 January, 2024	PH 1.16 PG (L) Cholinergic Antagonists	PA: 7.1 L: Define and classify neoplasia.  Describe the characteristics of neoplasia including gross, microscopy, biologic, behaviour and spread.  Differentiate between Benign from Maignant neoplasm	LUNCH BREAK	MI 1.2: Lab diagnosis of para (P), Batch A/B	asitic infections
48	Thursday, 1 February, 2024	MI 1.1, General Mycology + Overview of Fungal infections (L)	PA:7.2L: Describe the molecular basis of cancer.		PH2.2 Prepare oral rehydration solution from ORS packet and explain its	
49	Friday, 2 February, 2024	Discuss and describe the common causes, pathophysiology and manifestations of fever in various regions in India and viral causes (e.g Dengue,DHF, chikungunya)	PH 1.14-(SGD) Types, doses, side effects, indications and contraindications of adr drugs		CM 7.5(SGD) Enumerate, defi epidemiological study designs.	
50	Saturday, 3 February, 2024	SU3.1 Describe the Indications and appropriate use of blood and blood products and complications of blood transfusion.	FM 3.3,3.4 Mechanical Injuries		PH2.3 Demonstrate the appropriate intravenous simulated en	s drip in a
51	Sunday, 4 February, 2024		WEEKLYOFF			
52	Monday, 5 February, 2024	PA: 7.3 L: Enumerate carcinogens and describe the process of carcinogenesis	MI 1.3: Epidemiology of infectious diseases (L)		PA: 4.4 DOAP: Identify chronic inflammation in specin Gross & Slides : Acute cholecy	gross and microscopic nens appendicitis, Chronic

				PA:7.4 L: Describe the		FM2.18 Crime Scene	
				effects of tumour on the host		Investigation Practical	MI 8.5, 8.6:
				including		investigation Fractical	Biomedical waste (SDL)
53	Tuesday, 6 February, 2024	PH 1.16: Management of glaucoma		paraneoplastic syndrome			` ´
		- C		PA:7.5 L: Describe	İ		
				immunology & immune		MI 1.1, 1.2: Lab diagnosis	of fungal infections (P).
				response to cancer(N)		Batch A/B	
54	Wednesday, 7 February, 2024	PH 1.16: NSAID- L					
34	wednesday, / February, 2024	FII 1.10. NSAID- L		PA:8.1 SDL: Describe the		PH2.4 Demonstrate	
					LUNCH BREAK	the correct method of	
				diagnostic role of	Lerven Bittair		
				cytology and its application in		calculation of drug dosage in patients	
				clinical care.		including	
		MI 1.7: Immunological mechanisms in				those used in special	
55	Thursday, 8 February, 2024	health(Innate and Acquired) (L)				cituations	
				PH 1.16- (SGD) types,			
				doses, side effects, indications and		CM 7.5 (SDL) Enumerate, of	lefine, describe and discuss
				contraindications of:Cholinergic		epidemiological study desig	
56 57	Friday, 9 February, 2024	OG 4.1Fetus and Placenta		A ICATURDA VOEE			
58	Saturday, 10 February, 2024	<u> </u>		2nd S A T U R D A Y O F F W E E K L Y O F F			
38	Sunday, 11 February, 2024	DA: 0.2 CCD: Decembe the besis of		WEEKLYOFF	<u> </u>	n	1.51
		PA: 8.2 SGD: Describe the basis of		MI 1.8: Components of			A 5.1
		exfoliative cytology including the		immune system 1 (L)		SLIDE : GRAN	ULATION TISSUE
59	Monday, 12 February, 2024	technique & stains used		- 1			
				PA:8.3 SDL Observe a		FM4.11 Describe and	
				diagnostic cytology and its		discuss euthanasia SGD	MI 1.8: Antigen (SDL)
				staining and interpret			, , , , , , , , , , , , , , , , , , ,
60	Tuesday, 13 February, 2024	PH1.32: Gout (L)		the specimen			
				PA:9.1 SGD: Describe the			
		PH1.33: Drug reatment of Bronchial asthma (L)		principles and			
		1111.55. Drug featment of Bronemar asuma (L)		mechanisms involved in			
61	Wednesday, 14 February, 2024			immunity.		MI 1.2: Acid fast staining	(P) Batch A/B
				PA: 9.2 L: Describe the			
		MI 1.8: Components of immune system 2		mechanism of hypersensitivity	LUNCH BREAK		
		(L)		reactions.			
62	Thursday, 15 February, 2024						
		4.4 :Describe and discuss the pathophysiology and			İ		
		manifestations of inflammatory causes of fever					
		4.5 :Describe and discuss the pathophysiology and					
		manifestations of malignant causes of fever including					
		hematologic and lymph node malignancies					
				PH 1.26- (SGD) 5-HT		CM 7.6 (Lecture) Enume	rate and evaluate the need of
63	i			modulating Drugs		screening tests	
0.5	Friday, 16 February, 2024			8 8			
		SU3.3 Counsel patients and family/ friends for blood	AETCOM			Family Adopt	on Program
64	Friday, 16 February, 2024 Saturday, 17 February, 2024 Sunday, 18 February, 2024	SU3.3 Counsel patients and family/ friends for blood transfusion and blood donation.	AETCOM	FM 3.5 Mechanical Injuries WEEKLYOFF		Family Adopt	ion Program

		PA:9.3 L Describe the HLA system and the immune principles involved in transplant and mechanism of transplant rejection.			PA6.7 DOAP: Identify and describe the gross and microscopic features of infarction in a pathologic specimen slide.  Gross: Splenic Infarct Slide: Thrombosis.
66	Monday, 19 February, 2024		MI 1.8: Antibody (L) PA: 9.4 SGD Define and describe autoimmunity.		FM4.25 Clinical research & Ethics Discuss human
			Enumerate autoimmune disorders. (N)		experimentation including clinical trials SGD  MI 8.5, 8.6: Needle stick
67	Tuesday, 20 February, 2024	PH 1.24: Diuretics- (L)		LUNCH BREAK	injury (SGD)
			PA: 9.5 LECTURE: Define and describe the pathogenesis		MI 1.2: Stool microscopy 2 (P), Batch A/B
			of Systemic		
68	Wednesday, 21 February, 2024	PH 1.26: RAS- (L)	Lupus Erythematosus		
			PA: 9.6 SDL: DefINE and		PH3.1 Write a rational, correct and legible generic
			describe the pathogenesis and		prescription for a given condition and communicate the same to the
			pathology of HIV and AIDS		patient
69	Thursday, 22 February, 2024	MI 1.8: Antigen antibody reactions 1 (L)			<b>F</b> ************************************
	,,				CM 7.7(SGD)Describe and demonstrate the steps in the
		OG 6.1 Diagnosis of pregnancy			Investigation of an epidemic of communicable disease
70 71	Friday, 23 February, 2024 Saturday, 24 February, 2024		PH 1.28 PVD-SGD 4th S A T U R D A Y O F F		
72	Sunday, 25 February, 2024		WEEKLYOFF		
,-	,,		WEERETOTT		PA:7.1 DOAP: Define and classify neoplasia.
					Describe the characteristics of neoplasia including
		DA. 0.7.00D. Define and describe the			gross, microscopy, biologic, behaviour and spread.
		PA: 9.7 SGD: Define and describe the pathogenesis of other common			Differentiate between benign from maignant neoplams:
		autoimmune diseases(N)			Gross & Slides : Lipoma, Hemangioma
		,			g
	N 1 26 P.1 222		MI 1.8: Antigen antibody		
73	Monday, 26 February, 2024		reactions 2(L) PA:10.1 SDL: Define and		FM4.27 Describe and
			describe the pathogenesis and		discuss Ethical Guidelines
			pathology of malaria.		for Biomedical Research on
					Human Subjects & Animals SGD
					MI 1.10:
7.4	T1 27 F-1 2024	DIV 1 27 Days Assatus CHITAL (L)			Immunodeficiency
74	Tuesday, 27 February, 2024	PH 1.27: Drug treatment of HTN -(L)	PA: 10.2 SGD (IL): Define		disorders (SGD)
			and describe the pathogenesis		MT 10 0 15 1 11 11 11 11 11 11 11 11 11 11 11 1
			and pathology of cysticercosis.		MI 1.8, 8.15: Antigen- antibody reaction 1
					(P), Batch A/B
75	Wednesday, 28 February, 2024	PH 1.28-Drug treatment of Angina- (L)		LUNCH BREAK	

				PA:10.3 SGD (IL): Define and describe the pathogenesis			correct and legible generic n for a given
				and		condition and communic	cate the same to the patient
76	Thursday, 29 February, 2024	MI 1.8 Complement (L)		pathology of leprosy			
		4.8:Discuss and describe the pathophysiology, aetiology and clinical manifestations of fever of					
		unknown origin (FUO) including in anormal host,		PH 1.25-(SGD) Drugs used in		CM 7.8(Lecture) Describe	the principles of association,
		neutropenic host, nosocomial host, and a host with		shock		S C C C C C C C C C C C C C C C C C C C	n epidemiological studies
	T. 1 1 1 2004	HIV disease					
77	Friday, 1 March, 2024	SU5.1 Discuss normal wound healing and factors					
		affecting healing.				PH3.3 Perform and interpret	a critical appraisal (audit) of a
		SU5.2 Discuss history & presentation in a patient with				~	iven
78	Saturday, 2 March, 2024	wounds.	AETCOM	FM 3.6 Mechanical Injuries		preso	cription
79	Sunday, 3 March, 2024		ALTCOM	W E E K L Y O F F			
							e and classify neoplasia.
							tics of neoplasia including
		PA:10.4 Define and describe the					gic, behaviour and spread. benign from maignant
		pathogenesis and pathology of common bacterial, viral, protozoal and helminthic					plams
		diseases.				Slides: SCC &	Adenocarcinoma
				MI 1.8: Cell mediated			
80	Monday, 4 March, 2024			immune response (L)			
				PA:11.1 L: Describe		FM3.1 IDENTIFICATION	
		PH 1.31: Drug treatment of Arrhythmia-1		pathogenesis, features of common cytogenetic		Bone Examination DOAP	MI 1.11: Transplant and
		(L)		abnormality & mutations in			cancer immunology (SGD)
81	Tuesday, 5 March, 2024			childhood(N)			(4.5.)
				PA:11.2 SGD: Describe	LUNCH BREAK		
		PH1.25: : Drug treatment of		pathogenesis and pathology of tumour and tumour like			
		DYSLIPIDEMIA –(L)		conditions in infancy and		MI 1.8, 8.15: Antigen ant	ihody reactions 2 (P)
82	Wednesday, 6 March, 2024			childhood(N)		Batch A/B	
				PA:11.3 L: Describe			
				pathogenesis of common		PH3.4 Perform a critical	evaluation of the drug
				storage disorders in infancy and childhood(N)		promotional literature	
83	Thursday, 7 March, 2024	MI 1.8: Humoral immune response (L)					
				PH 1.25: (SGD) side effects, indications and contraindications			
				of the drugs used in congestive		CM 7.8(SGD) Describe t	he principles of association,
				heart failure		causation and biases in	n epidemiological studies
84	Friday, 8 March, 2024	OC 7.1 Dhysiological shapes of my					
		OG 7.1 Physiological changes of pregnancy					
85	Saturday, 9 March, 2024			2nd SATURDAYOFF			

		PA:12.1 SGD(IL) Enumerate and describe		MI 1.10:		PA 10.1	1 PA 10.2
		the pathogenesis of disorders caused by		Hypersensitivity			Malaria cysticercosis.
		air pollution, tobacco and alcohal.		reactions (L)			
87	Monday, 11 March, 2024						
- 67	Monday, 11 March, 2021			PA:12.2 SGD (IL) Describe the		FM 3.1 X-ray Shoulder	
				pathogenesis of disorders		Joint Elbow	
				caused by protein calorie		DOAP	
				malnutrition and starvation			
							MI 1.9:
88	Tuesday, 12 March, 2024	PH 1.35: Drug treatment of Anemia- (L)					Immunoprophylaxis
				PA: 12.3 SGD Describe the			
				pathogenesis of obesity and its			
				consequences			
89	Wednesday, 13 March, 2024	PH 1.35: Thrombolytics				MI 1.2: Acid fast staining	2 (P), Batch A/B
				PA: 13.1 SGD: Describe	LUNCH BREAK		
				hematopoiesis &	EUNCH BREAK	PH3.4 To recognise and	report an adverse drug
90	Thursday, 14 March, 2024			extramedullary hematopoiesis.		reaction	repert an adverse arag
		MI 1.10: Autoimmunity (L)					
		4.16:Enumerate the indications and describe the					
		findings in tests of inflammation and specific					
		rheumatologic tests, serologic testing for pathogens					
		including HIV, bone marrow aspiration and biopsy					
		4.18:Enumerate the indications for use of imaging in					
		the diagnosis of febrile syndromes					
				PH 1.25: Plasma Expanders-		CM 6.1 (Lactura) Formulata	a research question for a study
91	Friday, 15 March, 2024			(SGD)			research question for a study
	7/ - / -	SU5.3 Differentiate the various types of wounds, and					
		plan management of wounds. SU5.4 Discuss medico		EM272020 E			
		legal aspects of wounds		FM 3.7,3.8,3.9 – Firearm Injuries			
				injuries			
92	Saturday, 16 March, 2024		AETCOM			Family Adoption	on Program
93	Sunday, 17 March, 2024			WEEKLYOFF			
94	Monday, 18 March, 2024	PA 14.1 L Describe iron metabolism		MI 2.1, 2.2: Infections of CVS:			cribe hematopoiesis &
				Rheumatic fever & Infective Endocarditis including			y hematopoiesis.
0.5	T 1 10 1/ 1 202 :			****			e marrow slide
95	Tuesday, 19 March, 2024			PA:14.2 L Describe the		FM 1.9 Age Estimation DOAP	
				etiology, investigations		Estimation DOAP	
		DII 1 26. Temps in ordin (I.)		and differential diagnosis of microcytic hypochromic			MI 1 1, Plague (CDI)
96	Wednesday, 20 March, 2024	PH 1.36: Types insulin(L)		PA: 15.1 L : Describe the			MI 1.1: Plague (SDL)
90	rr culicouay, 20 Maicii, 2024			metabolism of Vitamin B12	LUNCH BREAK		annay nn
				and the etiology and		The second secon	s, CRBSI, RF, IE (P),
		PH 1.36- Drug management of DM-2 (L)		pathogenesis of B12 deficiency			Brucellosis, Borellia &
				patriogenesis of DIZ deficiency		Leptospir	rosis (SGD)
97	Thursday, 21 March, 2024	MICRO		PATHO			

98	Friday, 22 March, 2024						
		Obs & Gyne		PHARMA		COM	. MED.
		·					
99	Saturday, 23 March, 2024			4th SATURDAYOFF			
100	Sunday, 24 March, 2024			WEEKLYOFF			
101	Monday, 25 March, 2024			HOLI			
102	Tuesday, 26 March, 2024	PH 1.37: Ant-Platelet drgs (L)		PA:13.2 SGD: Describe the role of anticoagulants in hematology		FM 3.1 X-ray Pelvis and Lower Limb DOAP	MI 2.4: Infections causing anaemia (SGD)
				PA:13.3 SGD Define and classify Anemia	LUNCH BREAK	Actino Le	4 Infections : slides: myecetes prosy and PPE 1 (P), Batch A/B
103	Wednesday, 27 March, 2024	PH 1.36- Fibrinolytics- (L)					
104	Thursday, 28 March, 2024	MI 1.1: BSI, Sepsis, septic shock, CRBSI (L)		PA 13.4 SGD Enumerate and describe the investigations of anemia			
105	Friday, 29 March, 2024			GOODFRIDAY			
106	Saturday, 30 March, 2024	SU4.1 Describe Pathophysiology of Burns. SU4.2 Describe Clinical features, Diagnose type and extent of burns and plan appropriate treatment.		FM 3.10, 3.11,3.12 Regional injuries	LUNCH BREAK	CM 7.9(SGD) Describe a of computers in epidemio	nd demonstrate the application logy
106	Sunday, 31 March, 2024 Sunday, 31 March, 2024			WEEKLYOFF			
107	Suliday, 31 March, 2024	IA 1	IA 1	IA 1	1	IA 1	IA 1
108	Monday, 1 April, 2024	IAT	IA I	IAI		IAI	18.1
		IA 1	IA 1	IA 1	1	IA 1	IA 1
					LUNCH BREAK		
109	Tuesday, 2 April, 2024	<u> </u>			4		
110	Wednesday, 3 April, 2024	IA I	IA 1	IA I		IA I	IA I
110				PA: 15.2 L: Describe laboratory	†		
111	Thursday, 4 April, 2024	MI 3.3: Enteric fever (L)		investigations of macrocytic anemia.			
112	Friday, 5 April, 2024			JUMA-TUL-VIDA	•		
	V/ 1 / / 1						

		SU4.3 Discuss the medico legal aspects in burn injuries.  SU4.4 Communicate and counsel patients (burns) and families on the outcome and rehabilitation demonstrating empathy and care.		FM 4.2 Medical ethics, 4.3 Medical councils, 4.4 Medical register, 4.5 , 4.24 Rights/privileges of medical practitioner	LUNCH BREAK	DII2 5 To assure and available	n a list of D days for a sixua
113	Saturday, 6 April, 2024		AETCOM			case/condition	n a list of P-drugs for a given
114	Sunday, 7 April, 2024	<u> </u>		WEEKLYOFF		•	
		PA:15.4 SGD: Enumerate the differences and describe the distinguishing features of megaloblastic and non-megaloblastic macrocytic anemia(N)			LUNCH BREAK	PA: 13.5 DOAP: Perform peripheral blood	BLE SKILL n, Identify and describe the picture in anemia Malaria
				MI 1.1: Rickettsial			
115	Monday, 8 April, 2024			infections (L)			
116	Tuesday, 9 April, 2024			EID-UL-FITR*			
117	Wednesday, 10 April, 2024						
118	Thursday, 11 April, 2024	MI 2.7: HIV-1 (L)		PA:16.1 L: Define and classify haemolytic anaemia		MI 1.2, 3.4, 8.15: Gram s enteric fever (P), Batch A	taining, Lab diagnosis of /B
					LUNCH BREAK	CM 6.2(SGD)  Describe and discuss the principles and demonstrate the methods of collection and classification of	PH3.6 Demonstrate how to optimize interaction with pharmaceutical representative to get authentic information on drugs
119	Friday, 12 April, 2024	OG 8.1, 8.2 Antenatal care		PH-1.36- (Types, doses of Iron formulations (SGD)		statistical data	
120	Saturday, 13 April, 2024	OG 612) 612 Africandida care		2nd S A T U R D A Y O F F			
121	Sunday, 14 April, 2024			WEEKLYOFF			
	1	PA:16.2 L: Describe the pathogenesis and clinical features and hematologic indices					ntify and describe the
		of haemolytic anaemia					n Microcytic anemia. ocytic anemia
100		or naomory no unaomia		MAZ WW 2 (1)		Silue : Milei	ocytic unciliu
122	Monday, 15 April, 2024			MI 2.7: HIV-2 (L) PA: 16.3 L Describe the			
				pathogenesis, features, hematologic indices and peripheral blood picture of sickle cell anemia and thalassemia	LUNCH BREAK	FM 1.9 Age Estimation DOAP	MI 1.1: Trypanosomiasis (SGD)
123	Tuesday, 16 April, 2024	PH 1.37- Antithyrid Drugs (L)					
124	Wednesday, 17 April, 2024			PA:16.4 L: Describe the	Γ		
				etiology pathogenesis, hematologic indices and peripheral blood picture of Acquired haemolytic anaemia		MI 1.2: Gram staining 2 (P), Batch A/B	PH3.7 Prepare a list of essential medicines for a healthcare facility
125	Thursday, 18 April, 2024	MI 1.1: Dengue, Chikungunya and Zika (L)		PA			

					LUNCH BREAK	CM ( 2(SCD) D	1
		4775' 11 7 4 4 1 1 1			Leiven BREAR		discuss and demonstrate the atistical methods including test
		4.7:Discuss and describe the pathophysiology and					various study designs
106	F : 1 10 4 3 2024	manifestations of the sepsis		DILL 27 LIDT GCD		of significance in	various study designs
126	Friday, 19 April, 2024			PH 1.37 HRT- SGD			
		SU6.1 Define and describe the etiology and		FM 4.6, 4.7 Laws in relation to			
		pathogenesis of surgical Infections		medical practice FM 4.9			
127	Saturday, 20 April, 2024	r8	AETCOM	Medicolegal issues		Family Adoption	Program
128	Sunday, 21 April, 2024			MAHAVIRJAYANTI			
						PA 15.	3 DOAP
						Identify and describe th	e peripheral blood picture
		16.5 L: Describe the peripheral blood				of ma	crocytic
		picture in different haemolytic Anaemias				An	emia
		picture in unierent naemorytic Anaemias				Slide : Macı	ocytic anemia
				MI 2.5 & 1.1: Malaria,			•
129	Monday, 22 April, 2024			Babesiosis 1 (L)			
		PH 1.37 Estrogen & Prog & their analogues (L)		PA 16.7 SDL Discribe the		FM 3.6	MI 1.1: Viral
				correct technique to		Weapons Examination	hemorrhagic fever 2
				perform a cross		DOAP	(SGD)
130	Tuesday, 23 April, 2024			match			(3 2 )
	37 - 1			PA:17.1 L : Enumerate the	LUNCH BREAK		
				etiology, pathogenesis and	DONOII BILLIII		
						MI 2.7, 8.15: Lab diagno	sis of HIV and Dengue (P),
				findings in aplastic anemia(N)		Batch A/B, MI 1.1:	Schistosomiasis (SGD)
131	Wednesday, 24 April, 2024	PH 1.39: OCP (L)					
				PA:17.2 SGD: Enumerate the			
				indications and describe the		PH3 8 Communicate effe	ctively with a patient on the
				findings in bone marrow			r use of
				aspiration and biopsy(N)			
				, , , , , , , , , , , , , , , , , , ,		prescribed	l medication
132	Thursday, 25 April, 2024	MI 2.5 & 1.1: Malaria, Babesiosis 2 (L)					
						CM 2.2GMT Define emerg	ing and reemerging infections.
							tify factors responsible for
		OG 8.7,8.8 Antenatal care cont.		PH 1.36: Calcium balance (- SGD)			ce of these infectious diseases.
133	Friday, 26 April, 2024					8	
134	Saturday, 27 April, 2024			4th S A T U R D A Y O F F			
135	Sunday, 28 April, 2024						
133	Sunday, 20 April, 2024			WEEKLYOFF	<u> </u>	D : 40	1 DO 4 B
	1						2 DOAP
		PA18.1 SDL Enumerate and describe the				· ·	e peripheral blood picture
				MI 2.5: Leishmaniasis (L)			IL,CML
		causes of leucocytosis leucopenia				Slide : A	ML,CML
126	Manday 20 April 2024						
136	Monday, 29 April, 2024			DA. 49.21 . December the			
	1			PA: 18.2 L: Describe the			
				etiology, genetics,			
				pathogenesis		FM 1.9 Medical Cause of	
				classification, features,		Death	MI 1.1: Systemic mycosis
				hematologic features of		SGD	and candidiasis (SGD)
	1			acute leukemia		335	
137	Tuesday, 30 April, 2024	PH 1.40 Tt of infertility					

				PA: 18.2 L: Describe the			
				etiology, genetics,			
				pathogenesis classification,			
		PH 1.36: Drug management of Osteoporosis-		features, hematologic features			
		(L)		of chronic leukemia			
		(L)		oi chronic leukemia			
				N			
138	Wednesday, 1 May, 2024					MI 1.2: Acid fast staining	(3 (P), Batch A/B
				PA:19.1 SGD: Enumerate the			
				causes and describe the		PH4 1 Administer drugs	through various routes in a
				differentiating features of			ulated
				lymphadenopathy		environment u	sing mannequins
139	Thursday, 2 May, 2024	MI 2.5: Lymphatic filariasis (L)			LUNCH BREAK		
		4.6:Discuss and describe the pathophysiology and					
		manifestations of Malaria					
		4.22:Describe and discuss the pharmacology,					
		indications, adverse reactions, interactions of					
		antimalarial drugs and basis of resistance					
		C C				CM 6 4(SCD) Enurs and	e, discuss and demonstrate
		4.23:Prescribe drugs for malaria based on the species				No. of the second secon	
		identified, prevalence of drug resistance and national					es, simple statistical methods,
		program 4.24:Develop an appropriate empiric					sures of central tendency and
		treatment plan based on the patient's clinical and				disp	ersion
		immune status pending definitive diagnosis					
				PH-1.38 – (SGD) Drugs			
				used			
140	Friday, 3 May, 2024			in erectile dysfunction			
1.0				ereetiie typranetien		PH4.2 Demonstrate the effe	cts of drugs on blood pressure
							pressor
				FM 4.8 consumer protection act,		· ·	•
		SU6.2 Enumerate Prophylactic and therapeutic		4.10 Communication,			appropriate blockers) using
		antibiotics. Plan appropriate management		4.11 euthanasia			puter
				4.11 Cuthanasia		aided	learning
141	Saturday, 4 May, 2024		AETCOM				
142	Sunday, 5 May, 2024			WEEKLYOFF			
- 1.2	Sanday, Sinay, 202	DA.40.2 CCD. Describe the nother consistent		WEERETOTT		DA 16	6 DOAP
		PA:19.2 SGD: Describe the pathogenesis and					
		pathology of tuberculous lymphadenitis					olood smear and identify
							olytic
				MI 3.1: GI Infective		anaemi	a from it.
				syndromes (L)		Slide : Hemolytic aner	nia,Sicklie cell anaemia
1							
143	Monday, 6 May, 2024						
143	171011day, 0 171ay, 2027			PA:19.4 L Describe and			
1				discuss the pathogenesis,			
1				pathology and the		FM 1.9 Drunkenness	
				differentiating features of		Certificate	MI 3.5: Food poisoning
				Hodgkin's lymphoma			and AAD (SGD)
1				J		DOAP	
144	Tuesday, 7 May, 2024	PH-1.38: Corticosteroids (L)					
144	1 ucsuay, / May, 2024	111-1.56. Corticosteroius (L)	l		LUNCH BREAK		

145	Wednesday, 8 May, 2024	PH-1.41: (L) Anterior Pituitary hormones	PA:19.4 L Describe and discuss the pathogenesis, pathology and the differentiating features of non- Hodgkin's lymphoma		MI 2.6, 8.15: Malaria, L filariasis (P), Batch A/B	eishmaniasis & Lymphatic.	
143	wednesday, o May, 2024	MI 3.1: Cholera and halophilic vibrio infections (L)	PA:19.6 SDL: Enumerate and differentiate the causes of		and et	ith the patient with empathy thics on all	
146	Thursday, 9 May, 2024		splenomegaly.		aspects	of drug use	
		OG 14.1 Maternal pelvis and fetal skull			newer process of vaccine de	cribe Vaccine components and evelopment. Describe the role of	
	T.1 1034 2024		D.C.T.		vaccines in disease	e control & eradication.	
147	Friday, 10 May, 2024 Saturday, 11 May, 2024		PCT 2nd S A T U R D A Y O F F				
148	Sunday, 12 May, 2024 Sunday, 12 May, 2024		WEEKLYOFF				
117	Sunday, 12 may, 2021	PA-20.1 L: Describe the features of plasma cell	MI 3.1: Intestinal amoebiasis		PA:16.7 DOAP: Describe and Demonstrate the		
		myeloma	& Balantidiasis (L)			perform a cross match.	
150	Monday, 13 May, 2024	,	( )		•	<b>F</b>	
			PA:21.2 L: Classify and describe the etiology, pathogenesis and pathology of vascular and platelet disorders including ITP		FM 1.9 Drunkenness Certificate	MI 3.1: Intestinal cestodes and trematodes (SGD)	
151	Tuesday, 14 May, 2024	PH-1.41: (L) Drugs used in the treatment of infertility	Factor and a second management		DOAP	and it continues (8 32)	
152	Wednesday, 15 May, 2024	PH1.34: Prokinetic agents (L)	PA:21.3 L: Differentiate platelet from clotting disorders based on the clinical and hematologic features			ram staining, Lab diagnosis DEC (P) Batch A/B, SGD	
			PA:21.4 L: Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of disseminated intravascular coagulation	LUNCH BREAK	use of a) drug therapy,	the patient regarding optimal b) devices and c) storage of edicines	
153	Thursday, 16 May, 2024	MI 3.1: Intestinal nematodes 1 (L)					

154	Friday, 17 May, 2024	25.1:Describe and discuss the response and the influence of host, immune status, risk factors and comorbidities on zoonotic diseases (e.g.Leptospirosis, thypus ) 25.2:Discuss and describe the common causes, pathophysiology and manifestations of these diseases  25.8:Enumerate the indications for use of newer techniques in the diagnosis of these infections  SU7.1  Describe the Planning and conduct of Surgical audit		PH 1.34: uterine relaxants and stimulants – (SGD)		vaccination during pand	ribe the importance of routine emics. Describe the role of cination programmes.	
		Describe the Flamming and conduct of Surgical addit						
155	Saturday, 18 May, 2024		AETCOM	4.16 Bioethics		Family Adoption	on Program	
156	Sunday, 19 May, 2024			WEEKLYOFF				
157	Monday, 20 May, 2024	PA:21.5 L: Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of Vitamin K deficiency.		MI 3.1: Intestinal nematodes 2(L)		of tuberculous lymph	PA:19.3 DOAP: Identify and describe the features of tuberculous lymphadenitis in a gross and microscopic specimen	
				PA:22.1 L: Classify and describe blood group systems (ABO and RH)		FM 1.9 Injury Certificate DOAP	MI 3.6, 3.1: Helicobacter infections, campylobacter infections and Yersiniosis (SGD)	
158	Tuesday, 21 May, 2024	PH 1.34-Anti-Emetic agents- (L)			LUNCH BREAK			
		PH 1.4: General principles of Chemotherapy –		PA:22.2 SGD: Enumerate the indications, describe the principles, enumerate and demonstrate the steps of compatibility testing.		amoebiasis, giardiasis a Batch	b diagnosis of intestinal nd coccidian parasites (P), es A/B & GD	
159	Wednesday, 22 May, 2024	(L)						
160	Thursday, 23 May, 2024			BUDDHAPURNIMA PH 1.43- (SGD)				
161	Friday, 24 May, 2024	OG 13.1 (A) Physiology and mechanism		Chloramphenicol and tetracyclines	LUNCH BREAK	CM 14.1(Lecture) Define an	d classify hospital waste	
162	Saturday, 25 May, 2024							
163	Sunday, 26 May, 2024	of labour						
164	Monday, 27 May, 2024	PA:22.4 SGD: Enumerate blood components and describe their clinical uses.		MI 3.7: Agents of viral hepatitis 1 (L)		Hodgkin's lymphoma	and describe the features of in gross and microscopic cimen	
165	Tuesday, 28 May, 2024	PH 1.42- Penicillins – 1(L)		PA:22.5 L: Enumerate and describe infections transmitted by blood transfusion.		FM 1.9 Injury Certificate DOAP	MI 3.1: Viral gastroenteritis (SDL)	

	T				I		
				PA:22.6 L: Describe transfusion			
				reactions and enumerate the		MI 1.2, 3.2, 8.15: Stoc	ol microscopy, intestinal
				steps in the investigation of a			todes (P), Batch A/B
				transfusion reaction			( )//
166	Wednesday, 29 May, 2024	PH-1.42: Penicillins –2 (L)					
				PA 22.7			
				SGDEnumerate the			
				indications and describe		PH5.3 Motivate patient	s with chronic diseases to
				the principles andand	LUNCH BREAK	adhere to the prescribed	management by the health
				procedure of autologous	LUNCH BREAK	care p	provider
				transfusion			
167	Thursday, 30 May, 2024	MI 3.7: Agents of viral hepatitis 2 (L)					
107	Thursday, 50 May, 2024	25.1:Describe and discuss the response and the					
		influence of host, immune status, risk factors and					
		comorbidities on zoonotic diseases (e.g. Rabies) and					
		non-febrile infectious disease (e.g. Tetanus)					
		25.2:Discuss and describe the common causes,					
		pathophysiology and manifestations of these diseases					various methods of treatment
		25.8:Enumerate the indications for use of newer				=	4.2(SDL) Describe various
		techniques in the diagnosis of these infections				methods of treatme	ent of hospital waste.
168	Friday, 31 May, 2024			PH 1.43, 1.55-SGD			
169	Saturday, 1 June, 2024	SU7.2 Discuss the principles and steps of clinical	AETCOM	4.18 Medical Negligence		Family Adoptic	on Drogram
109	Saturday, 1 June, 2024	research in General Surgery	AETCOM	4.18 Medical Negligence		ганиу Ацори	on Frogram
170	Sunday, 2 June, 2024			WEEKLYOFF			
		PA 23.1 SDL Describe abnormal urinary		MI 4.1, 4.2, 4.3: Infective			
		findings in disease states andidentify and				PA 19.7 DOAP: Identify	and describe the gross
		describe common urinary abnormalities in		syndromes of skin and soft		specimen of an enlarged	spleen
171	Monday, 3 June, 2024	a clinical specimen		tissue (L)			
				PA 23.2 SGD Describe		FM 1.9 Dental Examination	MI 1.1: Hydatid disease
				abnormal findings in body		DOAP	and other parasitic
				fluids in various disease			infections of liver (SGD)
				States			(* - )
	L	511.4.40.60.11.11.11.11					
172	Tuesday, 4 June, 2024	PH-1.42: Cephalosporins- (L)					
				PA 23.3 SGD Describe and			
				interpret the abnormalities in			
				a panel containing			
				semen analysis, thyroid			
				function tests, renal function			
				tests or	V VINCOV DE		
				liver function tests	LUNCH BREAK		
						MI 3.8, 8.15: Viral hep	atitis, parasites causing
173	Wednesday, 5 June, 2024	PH-1.42 Cephalosporins-2				liver infection (P), Bate	ch A/B

Tuesday, 25 June, 2024  PH1.42: Aminoglycosides- 1 (L)  PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine  MI 1.2, 4.1, 4.3, 8.15: Gram of staphylococcal and strep Batch A	ent the relationship between treatment t compliance
176	ed to hospital waste
177   Sunday, 9 June, 2024   IA 2	
178	
179   Tuesday, 11 June, 2024   IA 2	IA 2
181   Thursday, 13 June, 2024   1A 2   1A	IA 2
181   Thursday, 13 June, 2024   1A.2   1A.	IA 2
183 Saturday, 15 June, 2024  184 Sunday, 16 June, 2024  185 Monday, 17 June, 2024  186 Tuesday, 18 June, 2024  187 Wednesday, 19 June, 2024  188 Thursday, 20 June, 2024  189 Friday, 21 June, 2024  190 Saturday, 22 June, 2024  191 Sunday, 23 June, 2024  192 Monday, 24 June, 2024  PA 24.2 L: Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease  PA 24.2 L: Describe and etiology and pathogenesis and pathologic features of actionma of the stomach  PA 24.4 L: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine  MI 1.2, 4.1, 4.3, 8.15: Gram of staphylococcal apathologic features of Tuberculosis of the intestine  RI 1.2, 4.1, 4.3, 8.15: Gram of staphylococcal apathologic features of Tuberculosis of the intestine	IA 2
184 Sunday, 16 June, 2024 185 Monday, 17 June, 2024 186 Tuesday, 18 June, 2024 187 Wednesday, 19 June, 2024 188 Thursday, 20 June, 2024 189 Friday, 21 June, 2024 190 Saturday, 22 June, 2024 191 Sunday, 23 June, 2024 191 Sunday, 23 June, 2024 192 Monday, 24 June, 2024 193 Tuesday, 25 June, 2024 194 Tuesday, 25 June, 2024 195 Tuesday, 25 June, 2024 196 Tuesday, 25 June, 2024 197 Tuesday, 25 June, 2024 198 Tuesday, 25 June, 2024 199 PA 24.2 L: Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease 190 Monday, 24 June, 2024 191 Tuesday, 25 June, 2024 192 Monday, 24 June, 2024 193 Tuesday, 25 June, 2024 194 PH1.42: Aminoglycosides-1 (L) 195 Tuesday, 25 June, 2024 196 PA 24.4 L: Describe and etiology and pathogenesis and pathologic features of carcinoma of the stomach 198 Tuesday, 25 June, 2024 199 PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine 190 Tuberculosis of the intestine 190 Tuberculosis of the intestine 190 Tuberculosis of the intestine 190 Tuberculosis of the intestine	IA 2
185 Monday, 17 June, 2024 186 Tuesday, 18 June, 2024 187 Wednesday, 19 June, 2024 188 Thirsday, 20 June, 2024 189 Friday, 21 June, 2024 190 Saturday, 22 June, 2024 191 Sunday, 23 June, 2024 191 Sunday, 23 June, 2024 192 Monday, 24 June, 2024 193 Tuesday, 25 June, 2024 194 PA 24.2 L: Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease 192 Monday, 24 June, 2024 193 Tuesday, 25 June, 2024 194 PH 1.42: Aminoglycosides-1 (L) 195 PA 24.4 L: Describe and etiology and pathologic features of carcinoma of the stomach 195 Tuesday, 25 June, 2024 196 PA 24.5 SGD: Describe and etiology and pathologic features of Tuberculosis of the intestine 198 Tuesday, 25 June, 2024 199 PA 24.5 SGD: Describe and etiology and pathologic features of Tuberculosis of the intestine 199 Tuesday, 25 June, 2024 190 PA 24.5 SGD: Describe and etiology and pathologic features of Tuberculosis of the intestine	IA 2
186 Tuesday, 18 June, 2024 187 Wednesday, 19 June, 2024 188 Thursday, 20 June, 2024 189 Friday, 21 June, 2024 190 Saturday, 22 June, 2024 191 Sunday, 23 June, 2024 192 Monday, 24 June, 2024  PA 24.2 L: Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease  PA 24.2 L: Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease  PA 24.2 L: Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease  PA 24.4 L: Describe and etiology and pathogenesis and pathologic features of carcinoma of the stomach  Tuesday, 25 June, 2024  PH1.42: Aminoglycosides-1 (L)  PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine  MI 1.2, 4.1, 4.3, 8.15: Gram of staphylococcal and strey Batch.	
187 Wednesday, 19 June, 2024 188 Thursday, 20 June, 2024 189 Friday, 21 June, 2024 190 Saturday, 22 June, 2024 191 Sunday, 23 June, 2024 192 Monday, 24 June, 2024  PA 24.2 L: Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease  PA 24.2 L: Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease  PA 24.4 L: Describe and etiology and pathogenesis and pathologic features of carcinoma of the stomach  Tuesday, 25 June, 2024  PH 1.42: Aminoglycosides- 1 (L)  PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine  MII 1.2, 4.1, 4.3, 8.15: Gram of staphylococcal and strey Batch.	
SUMMERVACATION	
SUMMERVACATION	
Friday, 21 June, 2024	
PA 24.2 L: Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease  Monday, 24 June, 2024  PA 24.2 L: Describe the etiology, pathogenesis, pathology, clinical and microscopic features of peptic ulcer disease  PA 24.4 L: Describe and etiology and pathogenesis and pathologic features of carcinoma of the stomach  PA 24.4 L: Describe and etiology and pathogenesis and pathologic features of carcinoma of the stomach  PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine  MI 1.2, 4.1, 4.3, 8.15: Gram of staphylococcal and strey Batch A	
PA 24.2 L: Describe the etiology, pathogenesis, pathology, clinical and microscopic features of peptic ulcer disease  MI 4.3: Streptococcal infections pertaining to skin (L)  PA 24.4 L: Describe and etiology and pathogenesis and pathologic features of carcinoma of the stomach  Tuesday, 25 June, 2024  PH 1.42: Aminoglycosides- 1 (L)  PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine  MI 1.2, 4.1, 4.3, 8.15: Gram of staphylococcal and strey Batch.	
pathology, microbiology, clinical and microscopic features of peptic ulcer disease  MI 4.3: Streptococcal infections pertaining to skin (L)  PA 24.4 L: Describe and etiology and pathologic features of carcinoma of the stomach  Tuesday, 25 June, 2024  PH 1.42: Aminoglycosides- 1 (L)  PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine  MI 1.2, 4.1, 4.3, 8.15: Gram of staphylococcal and strep Batch.	
PA 24.4 L: Describe and etiology and pathogenesis and pathologic features of carcinoma of the stomach  PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine  PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine  PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine	d demonstrate the steps of
PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine  PA 24.5 SGD: Describe and etiology and pathogenesis and pathogenesis and pathologic features of of staphylococcal and street and str	MI 4.3: Leprosy (SGD)
194 Wednesday, 26 June, 2024 PH 1.42: Aminoglycosides- 2 – (L)	reptococcal infections (P)

				PA 24.6 L: Describe and etiology and pathogenesis and pathologic and distinguishing features of Inflammatory			derstanding of the caution in bing drugs
			l	bowel disease			ence and recommend the line of agemen
195	Thursday, 27 June, 2024	MI 4.1: Gas gangrene and tetanus (L)					
173	Thatsaay, 27 vane, 202	OG 13.1 (B) Monitoring of labour and				CM 15.2 (Lecture) Descr	ibe warning signals of mental
		partogram/ LCG		PH1.42-(SGD)			GD)Describe warning signals of
196	Friday, 28 June, 2024			Aminoglycosides		mental he	ealth disorder
197	Saturday, 29 June, 2024	Revision		FM 4.20 legal provisions		Family Adopt	ion Program
198	Sunday, 30 June, 2024			WEEKLYOFF			
		PA 24.7 L: Describe the etiology, pathogenesis, pathology and distinguishing features of carcinoma of the colon				abnormalities in semen analysis, thyr	ribe and interpret the a panel containing roid function tests, renal
							on tests or etion tests (I)
199	Monday, 1 July, 2024			MI 4.3: Viral exanthems 1 (L) PA 25.1 SGD (IL): Describe bilirubin metabolism, enumerate the etiology and pathogenesis of jaundice, distinguish between direct and indirect		FM 1.9 MCCD DOAP	MI 4.3: Tissue nematode infections of skin and soft tissue (SGD)
				hyperbilirubinemia			
200	Tuesday, 2 July, 2024	PH:1.42: Macrolides- L					
200	Tuesday, 2 July, 2024	111.1.42. Macrondes- E		PA 25.2 SGD (IL):			
				Describe the pathophysiology			
				and pathologic changes seen			
				in hepatic failure and their			
				clinical manifestations,			
I				complications and			
				consequences.			
						MI 4.3, 8.15: Infect	ions due to non fermenters
201	Wednesday, 3 July, 2024	PH1.42:Fluroquinlones- (L)			LUNCH BREAK	(P) Batch A/B, SGE	

202	Thursday, 4 July, 2024	MI 4.3: Viral exanthems 2 (L)		PA 25.3 SGD (IL): Describe the etiology and pathogenesis of viral and toxic hepatitis: distinguish the causes of hepatitis based on the clinical and laboratory features. Describe the pathology, complications and consequences of hepatitis.		abou aspects of drug	y to educate public & patients t various use including drug and OTC drugs
202	Thursday, 19ary, 2021	23.4:Enumerate the indications for enteral and parenteral nutrition in critically ill patients				CM 15.3 (SDL) Describe	National Mental Health
203	Friday, 5 July, 2024	parenteral nutrition in critically in patients		PH1.42:Fluro-SGD		program	
							nderstanding of the legal and aspects of
204	Saturday, 6 July, 2024	Revision	AETCOM	FM 4.19 Consent			bing drugs
205	Sunday, 7 July, 2024			WEEKLYOFF			
		PA 25.4 L: Describe the pathophysiology, pathology and progression of alcoholic liver disease including cirrhosis		MI 4.3: Superficial, subcutaneous fungal infections (L)		abnormalities ir semen analysis, thyr functi	ribe and interpret the a panel containing roid function tests, renal on tests or tion tests(II)
206	Monday, 8 July, 2024			PA 25.5 L: Describe the etiology, pathogenesis and complications of portal hypertension Diseases of gall bladder		FM 1.9 MCCD DOAP	MI 8.5, 8.6, 8.7: Hospital acquired infections (SGD)
207	Tuesday, 9 July, 2024  Wednesday, 10 July, 2024	PH1.43-Sulphonamides – (L)  PH1.43-Cotrimoxazole-(L)		PA 26.1 L : Define and describe the etiology, types, pathogenesis, stages, morphology and complications of pneumonia	LUNCH BREAK	subcutaneous fungi (P	due to superficial and ) Batch A/B, cutaneous & is; Penicilliosis (SGD)
209	Thursday, 11 July, 2024	MI 5.1: Infective syndromes of CNS (L)		PA 26.2 SGD: Describe the etiology, gross and microscopic appearance and complications of lung abscess		agents	of neuro-muscular blocking
210	Eridov 12 July 2024	OG 13.1 (B) Monitoring of labour and partogram/ LCG		PH1.44: dugs used in MDR and XDR Tuberculosis - SGD		nutrients and special nutriti	the common sources of various onal requirements according to hysiological conditions
210 211	Friday, 12 July, 2024 Saturday, 13 July, 2024		L	2nd S A T U R D A Y O F F			
211	Saturday, 13 July, 2024			2110 SATUKDATUFF			

212	Sunday, 14 July, 2024			WEEKLYOFF			
213	Monday, 15 July, 2024	PA 26.3 L: Define and describe the etiology, types, pathogenesis, stages, morphology and complications and evaluation of Obstructive airway disease (OAD) and bronchiectasis		MI 5.1: Agents of pyogenic meningitis (L)		PA 24.1: DOAP Describe and identify the microscopic features of plepmorphic adenoma	
				PA 26.4 L: Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of tuberculosis	LUNCH BREAK	FM 1.9 Toxicology Specimen SGD	MI 5.1: Agents of aseptic meningitis 1 (SGD)
214	Tuesday, 16 July, 2024	PH1.48-Drug treatment of UTI- (L)					
215	Wednesday, 17 July, 2024			MUHARRAM*/ASHURA	<b>\*</b>		
				PA 26.5 SGD : Define and describe the etiology, types, exposure, environmental influence, pathogenesis, stages, morphology, microscopic appearance and complications of Occupational lung disease N		MI 1.2, 5.3, 8.15: Gram staining and agents of pyogenic meningitis (P) Batch A/B & SGD	MI1.6 Describe the mechanisms of drug resistance, methods of antimicrobial susceptibility testing and monitoring of antimicrobial therapy
					LUNCH BREAK		
216	Thursday, 18 July, 2024 Friday, 19 July, 2024	PH1.46-ATT- (L)  23.3:Discuss and describe the aetiology, causes, clinical manifestations, complications, diagnosis and management of common vitamin Deficiencies		PH 1.55: Side effects of Antileprotics –(SGD)		method of performing individuals, families and	and demonstrate the correct a nutritional assessment of the community by using the iate method
218	Saturday, 20 July, 2024	Assessment	AETCOM	FM 2.1 Death and its types, 2.2 Natural and Unnatural deaths, 2.3 sudden natural death		Family Adopt	on Program
219	Sunday, 21 July, 2024			WEEKLYOFF		•	
220	Monday, 22 July, 2024	PA 26.6 L: Define and describe the etiology, types, exposure, genetics environmental influence, pathogenesis, stages, morphology, microscopic appearance, metastases and complications of tumors of the lung and pleura		MI 5.2: Viral encephalitis 1 (L)		PA 24.3 : DOAP Descrit microscopic features of J	· · · · · · · · · · · · · · · · · · ·

			PA 26.7 L: Define and describe the etiology, types, exposure, genetics environmental influence, pathogenesis, morphology, microscopic appearance and complications of mesothelioma		FM 1.9 Toxicology Specimen SGD	
221	Tuesday, 23 July, 2024	PH1.46-ATT- (L)				MI 5.1: Agents of aseptic meningitis 2 (SGD)
221	rucsury, 25 July, 2024	THI.40-ATT-(E)	PA 27.1 SGD: Distinguish arteriosclerosis from atherosclerosis. Describe the pathogenesis and pathology of various causes and types of arteriosclerosis	LUNCH BREAK		eningitis (P), Batch A/B; MI pocysticercosis (SGD)
222	Wednesday, 24 July, 2024	PH1.46-Anti Leprotics- L	PA 27.2 SGD: Describe the etiology, dynamics, pathology types and complications of aneurysms including aortic aneurysm		discuss the the clinical course, the disease	nteric fever pathogens and e evolution of laboratory diagnosis of the ses caused them
223	Thursday, 25 July, 2024	MI 5.2: Viral encephalitis 2 (L) OG 13.1 (C) Conduct of labour and			CM 5.3(Lecture) Define	e and describe common nutrition-
		management of 3rd stage of labour	PH1.47: Prophylaxis and Management of MalariaSGD		related health disorders (inc	luding macro-PEM, Micro-iron, ir control and management
224	Friday, 26 July, 2024 Saturday, 27 July, 2024		ALCA TURBA VOEE			
226	Saturday, 27 July, 2024 Sunday, 28 July, 2024		4th S A T U R D A Y O F F WEEK L Y O F F			
		PA 27.3 SGD : Describe the etiology, types, stages pathophysiology, pathology and complications of heart failure	MI 1.1, 4.1: Tetanus and botulism (L)		PA 24.5 : DOAP Describ microscopic features of	oe and identify the Fuberculosis of intestine.
227	Monday, 29 July, 2024  Tuesday, 30 July, 2024	PH1.47- drugs used in Malaria,Antimalarial drugs (L)	PA 27.4 L : Describe the etiology, pathophysiology, pathology, gross and microscopic features, criteria and complications of rheumatic fever		FM 3.14 SEXUAL OFFENCE MICROSCOPIC EXAMINATION SEMEN SGD	MI 5.2: Parasites causing encephalitis (SGD)

				PA 27.5 L: Describe the		
				epidemiology, risk factors,		
				etiology, pathophysiology,		
				pathology, presentations,		
				gross and microscopic		
				features, diagnostic tests and		
				complications of ischemic		
				heart disease		
229	Wednesday, 31 July, 2024	PH1.47- ACTs (L)			LUNCH BREAK	MI 1.2: AFB Staining (P) Batch A/B
22)	Wednesday, 31 July, 2021	1111.17 110-15 (2)		PA 27.6 SGD: Describe the	Ecited BREAR	HI 122. HI D Staining (I ) Daten H D
				etiology, pathophysiology,		
				pathology, gross and		
				microscopic features, diagnosis		MI3.5 Enumerate the causative agents of food
				and complications of infective		poisoning and discuss the pathogenesis, clinical course
				endocarditis		and laboratory diagnosis
						, ,
		MI 6.1: Infective syndromes of Respiratory				
230	Thursday, 1 August, 2024	tract (L)				
	, ,					CM 5.5(Lecture) Describe the methods of nutritional
						surveillance, principles of nutritional education and
		16.1:Describe and discuss the aetiology of acute and				rehabilitation in the context of sociocultural factors. CM
		chronic diarrhea including infectious and non-				5.5 (SDL) Describe the methods of nutritional surveillance,
		infectious causes 16.6:Distinguish between diarrhea				principles of nutritional education and rehabilitation in the
		and dysentery based on clinical features		PH1.47:SGD Management of		context of sociocultural factors
231	Friday, 2 August, 2024			complicated malaria		
231	I may, 2 magust, 2027	SU8.1 Discuss the principles of Ethics as it pertains to		complicated materia		MI3.6 Describe the etio-pathogenesis of Acid Peptic
		General Surgery				Disease (APD) and
		SU8.2 Demonstrate Professionalism and empathy to		FM 2.4 Human organ		the clinical course. Discuss the diagnosis and management
		the patient undergoing General Surgery		transplantation 2.5 Moment and		of the
				modes of death		causative agent of APD
232	Saturday, 3 August, 2024		AETCOM			
233	Sunday, 4 August, 2024			WEEKLYOFF		
		PA 27.7 SGD: Describe the etiology,				PA 24.4,
		pathophysiology, pathology, gross and				Gross : Carcinoma of the stomach,
		microscopic features, diagnosis and				Slide: Carcinoma of the stomach,
		complications of pericarditis and pericardial				
		effusion				
22.4	Manufact 5 Account 2024			MI ( 1. Dielaharia (I )		
234	Monday, 5 August, 2024			MI 6.1: Diphtheria (L)		

			1			ENGO 14 CENTULA	
				PA 27.9 L: Classify and describe		FM 3.14 SEXUAL OFFENCE	
				the etiology, types,		MICROSCOPIC	
				pathophysiology, pathology,		EXAMINATION SEMEN	
				gross and microscopic		SGD	
				features, diagnosis and			
				complications of			
				cardiomyopathies N	LUNCH BREAK		MI 6.1:
225	T 1 6 4 2024	DYII 47 A 64 11 1 X					Parainfluenza and RSV
235	Tuesday, 6 August, 2024	PH1.47-AntiAmoebic drugs-L		PA 27.10 SGD: Describe the			(SGD)
				etiology, pathophysiology,			
				pathology features and		MI 6.2. Threat swah m	ram staining& URTI (P)
				complications of syphilis on			treptococcal infections
				the cardiovascular system		Datell A/D; SGD: St	treptococcai infections
236	Wednesday, 7 August, 2024	PH1.47-AntiFungal drugs-1 (L)					
230	wednesday, / August, 2024	FIII.47-Alidi dilgai diugs-1 (L)		PA 28.1 SDL : Describe the		CM2 9 Deganiha the ma	de of action & application
				normal histology of			mmonly used
			l .	the kidney			and rodenticides
237	Thursday, 8 August, 2024	MI 6.1: Viral URTI 1 (L)		the kidney		miscericides a	ind rodenticides
							rate and discuss the National
		OG 18.1, 18.3,18.4 Care of Newborn					national nutritional Programs
		Od 16.1, 16.5,16.4 Care of Newborn					Child Development Services
238	Friday, 9 August, 2024			PH 1.47: SGD Amebiasis		Scheme	(ICDS) etc.
239	Saturday, 10 August, 2024			2nd S A T U R D A Y O F F			
240	Sunday, 11 August, 2024			WEEKLYOFF			
		PA 28.2 L: Define, classify and distinguish the				PA 24.7,	
		clinical syndromes and describe the etiology,				Gross: Carcinom	
		pathogenesis, pathology, morphology, clinical				Slide : Carcinoma	of the colon
		and laboratory and urinary findings,					
		complications of renal failure					
241	Monday, 12 August, 2024			MI 6.1: Tuberculosis 1 (L)			
				PA 28.3 L : Define and describe		FM 2.23 DROWNING	
				the etiology, precipitating		, MICROSCOPIC	
				factors, pathogenesis,		EXAMINATION	
				pathology, laboratory urinary		DIATOM	MI 6.1: Viral URTI:
				findings, progression and		SGD	Rhinovirus, Adenovirus
				complications of acute renal	LUNCH BREAK		and EBV
				failure	LUNCH BKEAK		
242	Tuesday, 13 August, 2024	PH1.47-Anti Fungal drugs 2- (L)					

243 244	Wednesday, 14 August, 2024 Thursday, 15 August, 2024	PH1.48: Anti-viral drugs -1(L		PA 28.4 L: Define and describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings progression and complications of chronic renal failure		MI 6.3: Sputum gram staining (P) Batch A/B; MI 6.1: Agents of typical pneumonia (SGD)	CM19.1 Define and describe the concept of Essential Medicine List (EML)
245	Friday, 16 August, 2024	16.2 :Describe and discuss the acute systemic consequences of diarrhea including its impact on fluid balance 16.3 :Describe and discuss the chronic effects of diarrhea including malabsorption		SGD) Intestinal helminthesiasis	LUNCH BREAK	Describe and discuss the im	ood Hygiene CM 5.8: SGD portance and methods of food f additives and adulteration
246	Saturday, 17 August, 2024 Sunday, 18 August, 2024	SU8.3 Discuss Medico-legal issues in surgical practice	AETCOM	FM 2.6, presumptions, 2.7 suspended animation, 2.10 Time since death  WEEKLYOFF		Family Adoptic	on Program
		PA 28.5 L: Define and classify glomerular diseases. Enumerate and describe the etiology, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis				PA 25.6 DOAP Interpr hepatitis serology pane from non- obstructive j	BLE SKILL et liver function and viral l. Distinguish obstructive aundice based on clinical wer function test.
248	Monday, 19 August, 2024			MI 6.1: Tuberculosis 2 (L) PA 28.5 L : Define and classify glomerular diseases. Enumerate and describe the etiology, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis (II)		FM 2.28 DOAP session of ossification	MI 6.1: Fungal and parasitic agents causing
249	Tuesday, 20 August, 2024  Wednesday, 21 August, 2024	PH1.48: Anti-viral drugs-2(L) PHARMA		PA 28.6 L: Define and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, progression and complications of IgA nephropathy	LUNCH BREAK	MI 1.2 & 6.3: Lab diag staining (P), Batch A/E atypical pneumonia (Se	LRTI (SGD) gnosis of TB and AFB s; MI 6.1: Agents of

				PA 28.7 L : Enumerate and					
				describe the findings in		CM19.2 Describe roles of essential medicine in			
				glomerular manifestations of					
				systemic disease		primary health care			
251	Thursday, 22 August, 2024	MI 6.1: Sars Cov and Mers Cov (L)							
231	Thursday, 22 August, 2024	WIT 0.1. Sal's COV and Mel's COV (L)				CM 9.1(Lecture) Define and describe the principles of			
252	Friday, 23 August, 2024	OG 19.1 Puerperium		PH1.48: drugs used in :UTI/ STD SGD		Demography, Demographic cycle, Vital statistics			
253	Saturday, 24 August, 2024			4th S A T U R D A Y O F F					
254	Sunday, 25 August, 2024	WEEKLYOFF							
255	Monday, 26 August, 2024	JANMASHTAMI							
256	Tuesday, 27 August, 2024	PH1.48-Anti HIV- Drugs (L)		PA 28.8 SGD : Enumerate and classify diseases affecting the tubular interstitium  PA 28.9 SGD : Define and		FM2.29 Demonstrate respect to the directions of courts, while appearing as witness for recording of evidence under oath or affirmation, examination in chief, cross examination DOAP	MI 8.8: Bacteriology of air, milk and water and surface (SGD)		
257	Wednesday, 28 August, 2024	PH1.48-Anti HIV-HAART regimen (L)		PA 28.9 SGD: Define and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, progression and complications of acute tubular necrosis		PA 27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes Slide: Atheroma MI 1.3: Stool microscopy (P) Batch A/B; MI 1.1: Infective syndromes of eye SGD			
258	Thursday, 29 August, 2024	MI 7.3: Normal commensals of genitourinary tract and UTI (L)		PA 28.10 SGD: Describe the etiology pathogenesis pathology laboratory findings, distinguishing features progression and complications of acute and chronic pyelonephritis and reflux nephropathy	LUNCH BREAK	CM19.3 Describe counterprevention	ceit medicine and its		

	1	16.11 :Enumerate the indications for stool cultures						
		and blood cultures in patients with acute diarrhea						
		16.12 :Enumerate and discuss the indications for						
		further investigations including antibodies,						
		colonoscopy, diagnostic imaging and biopsy in the						
		diagnosis of chronic diarrhea						
		diagnosis of throme diagnosis						
						CM 9.1: (SDL)Define ar	nd describe the principles of	
259	Friday, 30 August, 2024			PH1.48-Anti HIV drugs (SGD)		Demography, Demogra	aphic cycle, Vital statistics	
		SU9.1 Choose appropriate biochemical,						
		microbiological, pathological, imaging investigations						
		and interpret the investigative data in a surgical patient						
260	Saturday, 31 August, 2024			FM 2.8 Postmortem changes		Family Adopti	on Program	
261	Sunday, 1 September, 2024		WEEKLYOFF					
		PA 28.11 L : Define classify and describe the						
		etiology, pathogenesis pathology, laboratory,						
		urinary findings, distinguishing features				PA 23.1 DOAP Describe	abnormal urinary findings	
		progression and complications of vascular				in disease states and ide	ntify and describe common	
		disease of the kidney				urinary abnormalitie	es in a clinical specimen	
262	Monday, 2 September, 2024			MI 7.2: Syphilis (L)				
				PA 28.12 L : Define classify				
				and describe the genetics,				
				inheritance, etiology,				
				pathogenesis, pathology,				
				laboratory, urinary		FM2.11 Describe and		
				findings, distinguishing		discuss autopsy procedures		
				features, progression and		including post-mortem		
				complications of cystic		examination, different types		
				disease of the kidney		of autopsies SGD		
							MI 7.1,7.2:	
							Gonococcal and non	
							gonococcal urethritis	
263	Tuesday, 3 September, 2024	PH1.49: Anticancer drugs 1- L					(SGD)	